How India Exports Spironolactone to the World

In the United States, spironolactone is approved for various indications, including the treatment of heart failure, hypertension, and edema. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for spironolactone, indicating a competitive generic market. Notably, Amneal Pharmaceuticals LLC received approval for its spironolactone oral suspension (25 mg/5 mL) under ANDA 215572 in October 2024. This approval underscores the active participation of Indian exporters in the U.S. market. As of March 2026, there are no FDA import alerts specifically targeting spironolactone, facilitating its continued importation into the U.S.

Within the European Union, the European Medicines Agency (EMA) has authorized spironolactone-containing products for human use. For instance, Qaialdo, containing spironolactone, received marketing authorization on May 26, 2023. This approval reflects the EMA's recognition of spironolactone's therapeutic value. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the approval and monitoring of spironolactone products. Compliance with EU Good Manufacturing Practice (GMP) standards is mandatory for manufacturers exporting to these regions, ensuring product quality and safety.

Spironolactone is included in the World Health Organization's Model List of Essential Medicines, highlighting its importance in global health. It is also listed in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality specifications across different markets.

In India, spironolactone is classified as a Schedule H drug under the Drugs and Cosmetics Act, requiring a prescription for dispensation. The National Pharmaceutical Pricing Authority (NPPA) regulates its pricing to ensure affordability. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC), ensuring compliance with national and international regulations.

Spironolactone's primary patents have expired, leading to a robust generic market with multiple manufacturers producing the drug. This competitive landscape contributes to its widespread availability and affordability globally.

In April 2025, the MHRA issued a Class 3 medicines recall for Urospir 50mg/5ml Oral Solution due to dosing calculation errors in the product information leaflet. This recall underscores the importance of accurate labeling and information dissemination. Additionally, in December 2023, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) recommended updates to the product information for furosemide-spironolactone combination products, emphasizing the need for ongoing safety monitoring and information updates.

These developments highlight the dynamic regulatory environment surrounding spironolactone, necessitating continuous vigilance and compliance from manufacturers and exporters.

India is a significant producer of Active Pharmaceutical Ingredients (APIs), including Spironolactone. However, the production of APIs often relies on Key Starting Materials (KSMs) and intermediates, many of which are imported from China. This dependency poses a risk, as any disruption in the supply of these materials can impact API production. For instance, in September 2020, China increased prices of KSMs by 10-20%, affecting the cost structure of Indian pharmaceutical manufacturers.

Recognizing this vulnerability, the Indian government has initiated measures to reduce reliance on Chinese imports. In November 2024, two greenfield plants were inaugurated under the Production Linked Incentive (PLI) scheme to manufacture critical molecules like Penicillin G and Clavulanic Acid, aiming to cut import dependence by half. Despite these efforts, the transition to self-reliance is ongoing, and the risk associated with raw material dependency remains pertinent.

Our proprietary trade data from 2022 to 2026 indicates a high concentration in Spironolactone exports from India. The top five exporters account for 90.2% of the total export value, with Zydus Lifesciences Limited alone contributing 54.1%. Such concentration poses a single-source risk; any operational or regulatory issues affecting these key suppliers could disrupt the global supply chain.

To mitigate this risk, the Indian government's PLI scheme aims to diversify and strengthen domestic API manufacturing. By incentivizing a broader base of manufacturers, the scheme seeks to reduce dependency on a few large suppliers and enhance supply chain resilience. However, the effectiveness of this initiative in the context of Spironolactone production is yet to be fully realized.

Global shipping routes, including the Red Sea and the Strait of Hormuz, are critical for the transportation of pharmaceutical products. Geopolitical tensions in these regions can lead to shipping delays and increased costs. Additionally, U.S.-China trade tensions have previously resulted in tariffs and export restrictions, affecting the availability and pricing of pharmaceutical raw materials.

These disruptions have tangible impacts on drug availability. For example, in December 2025, Pfizer discontinued the manufacturing of Aldactone tablets (Spironolactone) in 25 mg and 100 mg formulations, leading to shortages in the U.S. market. Similarly, Health Canada reported Spironolactone shortages in July 2025 due to manufacturing disruptions and increased demand. (canada.ca)

• Diversify Supplier Base: Encourage the development of multiple suppliers for Spironolactone and its raw materials to reduce dependency on a few key players.

• Enhance Domestic Production: Accelerate initiatives under the PLI scheme to bolster domestic manufacturing of KSMs and APIs, reducing reliance on imports.

• Strengthen Supply Chain Monitoring: Implement robust monitoring systems to detect early signs of geopolitical or logistical disruptions that could impact the supply chain.

• Develop Strategic Reserves: Establish reserves of critical raw materials and finished products to buffer against short-term supply disruptions.

• Foster International Collaboration: Engage in partnerships with other countries to create alternative supply routes and share best practices in supply chain resilience.

RISK_LEVEL: MEDIUM